NervGen Pharma Corp.
NGEN:TSX.V; NGENF:OTCQX
NervGen is a publicly traded biotech company dedicated to discovering and developing treatments for patients suffering from medical conditions related to nerve damage.
Streetwise Company Fact Sheet2026/6/10 6:53:19
(NGEN:TSX.V - NGENF:OTCQX)
Analyst coverage
| Raymond James — Michael Freeman |
| Stifel — Justin Keywood |
| Paradigm Capital — Scott McAuley |
| Maxim Group — Michael Okunewitch |
| Lucid Capital Markets — Elemer Piros |
| H.C. Wainwright & Co. — Raghuram Selvaraju |
| Research Capital Corporation — Dr. Andre Uddin |
Newsletter coverage
| — |
Streetwise Reports Articles
| 05/28/2026 - View Article |
| 04/28/2026 - View Article |
| 12/16/2025 - View Article |
| 06/11/2024 - View Article |
Streetwise - NervGen Pharma Corp. Ownership Overview*
NervGen Pharma Corp. (NGEN:TSX.V; NGENF:OTCQX)
Restructures
No Restructures for This Company
*Share Structure as of 5/27/2026
© 2026 Streetwise Reports. All rights reserved.
Streetwise Reports is registered with the U.S. Patent and Trademark Office.
